Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 9
2012 13
2013 7
2014 4
2015 5
2016 5
2017 2
2018 7
2019 11
2020 8
2021 6
2022 11
2023 10
2024 10
2025 7
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, Thirunavukkarasu S, Khosravani H, Appireddy R, Moreau F, Gubitz G, Tkach A, Catanese L, Dowlatshahi D, Medvedev G, Mandzia J, Pikula A, Shankar J, Williams H, Field TS, Manosalva A, Siddiqui M, Zafar A, Imoukhuede O, Hunter G, Demchuk AM, Mishra S, Gioia LC, Jalini S, Cayer C, Phillips S, Elamin E, Shoamanesh A, Subramaniam S, Kate M, Jacquin G, Camden MC, Benali F, Alhabli I, Bala F, Horn M, Stotts G, Hill MD, Gladstone DJ, Poppe A, Sehgal A, Zhang Q, Lethebe BC, Doram C, Ademola A, Shamy M, Kenney C, Sajobi TT, Swartz RH; AcT Trial Investigators. Menon BK, et al. Lancet. 2022 Jul 16;400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29. Lancet. 2022. PMID: 35779553 Clinical Trial.
Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.
Field TS, Dizonno V, Almekhlafi MA, Bala F, Alhabli I, Wong H, Norena M, Villaluna MK, King-Azote P, Ratnaweera N, Mancini S, Van Gaal SC, Wilson LK, Graham BR, Sposato LA, Blacquiere D, Dewar BM, Boulos MI, Buck BH, Odier C, Perera KS, Pikula A, Tkach A, Medvedev G, Canfield C, Mortenson WB, Nadeau JO, Alshimemeri S, Benavente OR, Demchuk AM, Dowlatshahi D, Lanthier S, Lee AYY, Mandzia J, Suryanarayan D, Weitz JI, Hill MD; SECRET Investigators. Field TS, et al. Stroke. 2023 Nov;54(11):2724-2736. doi: 10.1161/STROKEAHA.123.044113. Epub 2023 Sep 7. Stroke. 2023. PMID: 37675613 Free PMC article. Clinical Trial.
Area Postrema Syndrome.
Camara-Lemarroy CR, Abo Al Sahm D, Boyko M, Jenkins J, Krett JD, Yeung M. Camara-Lemarroy CR, et al. Among authors: boyko m. Neurohospitalist. 2019 Jul;9(3):174-175. doi: 10.1177/1941874418809879. Epub 2018 Nov 14. Neurohospitalist. 2019. PMID: 31244977 Free PMC article. No abstract available.
Brain-derived tau for monitoring brain injury in acute ischemic stroke.
Vlegels N, Knuth NL, Steiner KA, Zhang L, Vix AL, Moumin D, Mirzen I, Khalifeh N, Forster C, Gesierich B, Müller F, Lohse P, Filler J, Fang R, Klein M, Dimitriadis K, Franzmeier N, Liebig T, Endres M, Goertler M, Petzold GC, Wunderlich S, Zerr I, Field TS, Pham M, Swartz RH, Poli S, Berrouschot J, Zafar A, Schneider H, Shankar JJ, Aamodt AH, Minnerup J, Mandzia JL, Reimann G, Psychogios MN, Mundiyanapurath S, Reich A, Yeo LLL, Duering M, Reidler P; DEMDAS study group; ESCAPE-NEXT biomarker substudy investigators‡; Goyal M, Tymianski M, Hill MD, Dichgans M, Tiedt S; DEMDAS study group collaborators; ESCAPE-NEXT biomarker substudy investigators. Vlegels N, et al. Sci Transl Med. 2026 Jan 14;18(832):eadz1280. doi: 10.1126/scitranslmed.adz1280. Epub 2026 Jan 14. Sci Transl Med. 2026. PMID: 41533774
Thrombolysis With Tenecteplase for Minor Disabling Stroke: Secondary Analysis of the TEMPO-2 Randomized Clinical Trial.
Zhang Y, Buck BH, Barber PA, Chatterjee K, Clarke B, Choi PMC, Hunter G, Ganesh A, Mishra SM, Williams D, Campbell BCV, Dowlatshahi D, Butcher KS, Krishnan K, Wiggam MI, Kleinig TJ, Muir KW, Zerna C, Field TS, Goyal M, Yu AYX, Roffe C, Demchuck AM, Parsons MW, Bazan R, Ankolekar S, Kennedy J, Menon BK, Mandzia JL, Pille A, Kelly PJ, Marko M, Singh N, Vatanpour S, Lima FO, Catanese L, Horn M, Ghia D, Ferrari J, Greisenegger S, Hill MD, Coutts SB; TEMPO-2 Investigators. Zhang Y, et al. JAMA Neurol. 2025 Dec 1;82(12):1243-1250. doi: 10.1001/jamaneurol.2025.4152. JAMA Neurol. 2025. PMID: 41143808 Clinical Trial.
104 results